Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share price taken down

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 17, 2021 8:13am

144 Views

Post# 33212775

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price taken down

GameChangerBet wrote:

woundedknee wrote:
Are any of these big pharmas even aware that Antibe exists? If so why has there not yet been any indication of colaborations (other than Nuance) at this stage in the game. For example Ventripoint (V.VPT) just recently made a colaboration agreement with GE Healthcare. Ventripoint is still a venture listed company trading at 40 cents give or take. So why the arguement (which I have supported) that we need to uplist to Naz and commence Phase 3 before we see big US pharmas get involved? Is there something that we are not being told? Dan's past record of being upfront and transparent, some would say, is less than stellar. To be clear, I believe in the product, but wonder if this road management has put us on is longer than neccessary.

Nasdaq uplist is for attracting U.S institutional investors. Has nothing to do with Big Pharma.
Big Pharma agreement can occur at any time.

But ... the NASDAQ will likely have an effect on future share price - via the institutional investor base and a larger future following.

And I will bet that ATE could have made deals with Big Pharam already - but they would have been sub-optimal deals.

Why only a Nuance deal and no other deals? Simply put ... the Nuance deal was strategic from the point of raising cash and buying time. Why buy time? To prove the value of the IP.

That's all in my opinion only.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features